Office of Technology Transfer – University of Michigan

Breast Cancer Targeted Therapy

Technology #3524

Background

Breast cancer is the most common cancer among women worldwide and is the second most common cause of cancer death in women in the United States. Early detection and new treatments have improved survival rates of breast cancer. Particularly, a number of genes involved in the development and progression of breast cancer have abnormalities in breast cancers. Analysis of these genes for diagnosis before the development of breast cancer might be a powerful predictor of the susceptibility to a breast cancer, the aggressive nature of a breast cancer and even the tailored therapeutic treatments.

Technology

Researchers at the University of Michigan have determined that one gene, AGTR1 is over-expressed and amplified in 10-20% of breast tumors, all of which were estrogen receptor positive and had low ERBB2 expression. Therefore AGTR1 could provide novel diagnostic markers for breast cancer. Treatment of breast cancer cell lines with angiotensin II, the ligand for AGTR1, caused a marked increase in invasion of breast cancer cell lines over-expressing AGTR1. This effect was attenuated by treatment with losartan, a highly specific AGTR1 blocker.

Applications and Advantages

Applications

  • Diagnostic markers for breast cancer
  • Therapeutic targets for breast cancer

Advantages

  • This invention provides novel breast cancer-nl-diagnostic markers
  • This invention provides new methods of-nl-treatment for breast cancer by using-nl-commercially available AGTR1 blocker drugs.